Citations

Clear

42 citation(s) found for "Tate, M".

CTNI-41. RESULTS OF A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE 2 STUDY OF THE RADIOPHARMACEUTICAL [177LU]LU-DOTA-TATE IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIOMA
Kurz, Sylvia C. , Zan, Elçin , Lobbous, Mina , Malkin, Mark G. , Miller, Alexandra , Torres-Trejo, Alejandro, Stevens, Glen , Zagzag, David , Golfinos, John G. , Shepherd, Timothy M. , Friedman, Kent, Cordova, Christine , Barbaro, Marissa , Dhawan, Andrew , Silverman, Joshua S. , Snuderl, Matija , Kondziolka, Douglas , Troxel, Andrea B. , Sulman, Erik P.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v135-v135

10.1093/neuonc/noaf201.0537 Get It

Abstract BACKGROUND Most meningiomas are considered benign tumors, however, a subset of meningiomas are characterized by a more aggressive clinical course and require multimodal treatment. Beyond surgery and radiation, there are no effective medical treatments available. Somatostatin receptor 2 (SSTR2) is expressed by the majority of meningiomas. [177Lu]Lu-DOTA-TATE (177Lu-Dotatate) is a SSTR2-targeting radioligand therapeutic agent that has been successful in other oncological entities, including neuroendocrine tumors. Here we report the results of a phase 2 clinical trial (NCT03971461) evaluating 177Lu-Dotatate in patients with advanced and treatment-refractory intracranial meningiomas. METHODS In this multicenter, open-label, phase 2 study, adults with advanced intracranial meningiomas received 177Lu-Dotatate at 7.4 GBq (200 mCi) every eight weeks for four doses. [68Ga]Ga-DOTA-TATE (68Ga-Dotatate) PET was performed before and at the end of treatment. The primary endpoint was progression-free survival at 6 months (PFS-6). Correlative studies evaluated the association of PFS-6, objective response rate, progression-free survival, overall survival with radiographic tumor measurements, and 68Ga-Dotatate uptake on PET. RESULTS Thirty-two patients (F=21, M=11) with progressive meningiomas (WHO 1=7, WHO 2=24, WHO 3=1) were enrolled. Median age was 65.5 (range 41-78) years. All patients previously underwent tumor resection and at least one course of radiation. Three patients (9%) had received medical therapy. Treatment with 177Lu-Dotatate was well tolerated, no treatment-limiting toxicities were observed. Of 29 evaluable patients at the data cutoff, 19 patients (66%) had achieved PFS-6 (WHO 1=4, WHO 2=15). Radiographically, the best response was partial response (PR) in 2 patients (6%) and stable disease (SD) in 20 patients (63%). CONCLUSIONS Treatment with SSTR2-targeting 177Lu-Dotatate is well tolerated and 66% of patients achieved PFS-6, comparing favorably to historical benchmarks, 177Lu-Dotatate therefore may be a useful new therapeutic modality for patients with advanced meningiomas and will be further explored in MOMENTUM-1 (NCT#06955169), an open-label, randomized, phase 2 trial.
RADT-50. SAFETY AND FEASIBILITY OF YTTRIUM-90 GLASS MICROSPHERE RADIATION THERAPY IN RECURRENT GLIOBLASTOMA: RESULTS FROM THE FIRST 12 PATIENTS TREATED IN THE FRONTIER TRIAL
Ansari, Sameer , Tate, Matthew C. , Lukas, Rimas V. , Butowski, Nicholas , Narsinh, Kazim , Boockvar, John A. , Serulle, Yafell , Middlebrooks, Erik H. , Basarabescu, Franco, Eldridge, Amanda , Ryan, Samantha , Dreher, Matthew R., Mouli, S. , Middlebrooks, Erik H , Stupp, Roger , Dixit, Karan , Weinstein, Jonathan, Trifiletti, Daniel M. , Kennedy, Paul , Ryan, Samantha M. , Salem, Riad

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v103-v104

10.1093/neuonc/noaf201.0419 Get It

Abstract BACKGROUND Glioblastoma (GBM) is highly aggressive with poor prognosis, especially in recurrent cases where treatments are limited. Intra-arterial (IA) Yttrium-90 (Y90) microsphere therapy, FDA-approved for hepatocellular carcinoma, offers the potential for targeted radiotherapy in recurrent GBM (rGBM). The FRONTIER trial evaluated the safety and feasibility of IA Y90-glass microsphere treatment for rGBM under an FDA Investigational Device Exemption. Materials and METHODS This prospective, single-arm, multi-center study included patients with rGBM in non-dominant, non-eloquent regions. The primary endpoint was 30-day incidence of treatment-related limiting toxicities (primarily ≥grade 3 non-hematologic, with exclusions). Secondary endpoints included adverse event (AE) rate, neurological changes, technical success (PET absorbed dose within ±20% of target), and efficacy. Treatment regions, defined via cerebral angiography-MRI fusion to cover the recurrent lesion, were targeted with 40±4Gy. Post-treatment evaluations included MRI, Y90-PET, and neurological assessments. RESULTS The procedure was well-tolerated by all twelve subjects and discharge occurred the following day with no decline in neurologic status. No limiting toxicities or device-related AEs were reported. Five patients experienced 8 procedure-related AEs (6 Grade 1, 2 Grade 3). Technical success was 100%, with post-treatment Y90-PET derived median absorbed dose of 41.5 Gy to the treatment region (median volume 80.3 cc). The median tumor absorbed dose was considerably higher at 124.2 Gy (median tumor volume 5.8 cc), indicating preferential tumor perfusion. At 2 months, 67% had stable disease, and 33% showed reduced T1-contrast enhancing volume within the treated area. Median progression-free survival was 3.1 (95% CI 0.92-NE) and overall survival (OS) was 9.3 months (95% CI 5.0-NE) from Y90 treatment. Exploratory analysis revealed a significant OS benefit for patients receiving a tumor absorbed dose above the median (11.9 vs 5.7 months, p=0.0073). CONCLUSION Results from this initial cohort suggest IA Y90-microsphere therapy is technically feasible and well-tolerated in rGBM. Further investigation is warranted.
Surgical Treatment of Brain Tumor-Related Epilepsy: Current and Emerging Strategies
Khalili, Bobak F. , Chojnacki, Michael R., Dixit, Karan , Gururangan, Kapil , Rosenow, Joshua M. , Hsieh, Jason , Magill, Stephen T. , Tate, Matthew C. , Lukas, Rimas V. , Templer, Jessica W. , Rosenow, Joshua M , Magill, Stephen T , Lukas, Rimas V , Templer, Jessica W , Horbinski, Craig

Mayo Clinic

Cancers | November 3, 2025 | Volume: 17 | Issue: 21 | Pages: 3539

10.3390/cancers17213539 | PMID 41228332 Get It

Brain tumor-related epilepsy (BTRE) is a common and debilitating symptom of central nervous system (CNS) tumors. The epileptogenic zone, defined as cortex responsible for seizure generation, is located at the peritumoral region for most tumors, and lower-grade intrinsic brain tumors have the highest seizure incidence. Surgery is often the most effective treatment for the reduction in seizures in BTRE. However, surgical decisions have historically often been made exclusively for oncologic reasons, with less emphasis on seizure control. Surgical approaches for all tumor types are reviewed, highlighting relevant risk factors. Adjunctive tools during surgery, such as intraoperative electrocorticography (ECoG), may help identify and remove surrounding brain areas which are epileptogenic. Minimally invasive surgery is also gaining traction, given its utility in treating seizures deep-seated tumors. This review explores epileptogenic brain tumors, surgery for BTRE, and emerging strategies to better achieve seizure control.
Abstract 4367364: A Multicenter Friedreich Ataxia Registry Identifies Posterior Wall Thickness as a Predictor of Major Adverse Cardiac Events
Dedio, Anna, McSweeney, K., Fournier, Anne , Yoon, Grace , Payne, R. Mark , Cripe, Linda , Patel, Aarti , Johnson, Jonathan N. , Lynch, David T. , Tate, Barbara , Feng, Yixuan , Mercer‐Rosa, Laura , Lin, Kimberly Y. , Niaz, Talha , McCormack, Shana Erin , Tate, Barbara, Feng, Yixuan, Huang, Jing Yang

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4367364 Get It

Background: Cardiac disease is the leading cause of premature mortality in Friedreich Ataxia (FA). However, validated prognostic indicators or early imaging biomarkers that can reliably predict cardiac events are lacking. To address this gap, we created a multicenter FA cardiac registry to characterize disease progression and identify early echocardiographic (echo) predictors of major adverse cardiac events (MACE). Methods: FA subjects from 6 North American centers with at least two echos performed ≥5 years apart were included. Demographics, FA-specific disease characteristics, and MACE (a composite of death, heart failure hospitalization, aborted sudden cardiac death, and/or life-threatening arrhythmia) were abstracted. Digital echo images were re-read at a centralized core lab. Paired T tests were utilized for comparison of the normally distributed first and second echo parameters, and logistic regression models were utilized to evaluate for predictors of MACE. Results: Of 115 subjects, 52 (45%) were female. Mean age at diagnosis was 10 ± 3 years, median GAA1 repeat length (a marker of genetic severity) was 700 (range 66–1200), and median age at first analyzed echo was 12 years (range 4-36). MACE occurred in 35 (30%) of the cohort. Serial echocardiograms demonstrated progressive worsening of multiple cardiac parameters over time, including markers of ventricular thickness and hypertrophy, chamber size, systolic function, and novel markers of atrial and ventricular strain (Table 1). On univariate analysis, several markers of hypertrophy and systolic function from the earliest analyzed echo predicted MACE. However, after adjusting for age of diagnosis, GAA1 repeat length, and collinearity among variables, only posterior wall thickness in diastole (PWTd) remained an independent predictor of MACE (odds ratio 1.8 per mm increase, 95% CI 1.1–3.3, p = 0.028). Conclusions: This multicenter FA registry identifies early posterior wall thickness as a significant and independent predictor of major adverse cardiac events in FA. Each millimeter increase in PWTd on early echo is associated with nearly double the odds of MACE. This commonly acquired parameter is often overlooked and may serve as a powerful early marker of cardiac risk. Further investigation of PWTd as a potential surrogate endpoint for therapeutic trials in FA is warranted.
P17.35.B SAFETY AND FEASIBILITY OF YTTRIUM-90 GLASS MICROSPHERES IN RECURRENT GLIOBLASTOMA: RESULTS FROM THE FIRST 12 PATIENTS TREATED IN THE FRONTIER TRIAL
Ansari, S, Butowski, Nicholas , Narsinh, Kazim , Boockvar, John A. , Weinstein, Jonathan D. , Serulle, Yafell , Middlebrooks, Erik H. , Basarabescu, Franco, Boucher, Éveline , Dreher, Matthew R., Salem, R., Mouli, S. , Middlebrooks, Erik H , Stupp, Roger , Tate, M, Weinstein, J, Trifiletti, Daniel M. , Kennedy, Paul , Eldridge, A

Mayo Clinic

Neuro-Oncology | October 3, 2025 | Volume: 27 | Issue: Supplement_3 | Pages: iii163-iii164

10.1093/neuonc/noaf193.551 Get It

Abstract BACKGROUND Glioblastoma (GBM) is highly aggressive with poor prognosis, especially in recurrent cases where treatments are limited. Intra-arterial (IA) Yttrium-90 (Y90) microsphere therapy, CE-marked for hepatic neoplasia, offers the potential for targeted high-dose beta radiation in GBM by leveraging tumor hypervascularity. The FRONTIER trial evaluated the safety and feasibility of IA Y90-glass microsphere treatment for recurrent GBM. MATERIAL AND METHODS FRONTIER is a prospective, single-arm, multi-center study with Investigational Device Exemption approval from the US FDA. This initial cohort included patients with recurrent GBM in non-dominant, non-eloquent regions after 1-2 lines of prior therapy. The primary endpoint was the 30-day incidence of treatment-related toxicities (primarily ≥grade 3 non-hematologic, with exclusions). Secondary endpoints included overall treatment-related adverse events (AE), neurological function changes, technical success, and efficacy measures. Treatment regions, defined via cerebral angiography-MRI fusion to cover the recurrent lesion were targeted with 40±4Gy. Post-treatment evaluations included MRI, Y90-PET for absorbed dose distribution, and serial neurological assessments. Changes in post-contrast T1-enhancing tissue volume (T1C-vol) were tracked longitudinally. RESULTS Twelve subjects (67% male; average age 57 years) were treated. The procedure was well-tolerated with no limiting toxicities reported or device-related AEs reported. Five patients experienced 8 procedure-related AEs (6 Grade 1, 2 Grade 3). At discharge one day after treatment, there was no decline in neurologic status per NIHSS. Technical success was 100%, with post-treatment Y90-PET showing a median absorbed dose of 41.5 Gy (range 39.2-45.4) to the treatment region (median volume 80.3 cc [40.9-118.5]). The median tumor absorbed dose was significantly higher at 124.2 Gy (range 58.5-508.5) within a median tumor volume of 5.8 cc (range 0.5-55.4), indicating preferential tumor perfusion. At 1 month, the best response was partial response in 17% (2/12), stable disease (SD) in 67% (8/12), and progressive disease in 17% (2/12). At 2 months, 73% (8/11 evaluable) had SD, and 33% (4/12) showed reduced T1C-vol within the treated area. Median progression-free survival was 3.0 (95% CI 1.1-3.7) and median overall survival (OS) was 9.3 months (95% CI 5.0-NE) from Y90 treatment. Exploratory analysis revealed a significant OS benefit for patients receiving a tumor absorbed dose above the median (>124 Gy) compared to those below (13.1 vs 5.8 months, p=0.0054). CONCLUSION Results from this initial cohort of the FRONTIER trial suggest IA Y90 glass microsphere therapy is technically feasible and well-tolerated in patients with recurrent GBM. The observed dose-response relationship warrants further investigation of this modality as a potential treatment option.
Precision Prevention, Diagnostics, and Treatment of Obesity: Pipedream or Reality?
Woolf, Emily K. , Diktas, Hanim E. , Acosta, Andrés , Apolzan, John W. , Ard, Jamy D. , Boyle, Kristen E. , Katzmarzyk, Peter T. , Nicastro, Holly L. , Redman, Leanne M. , Stephens, Jacqueline M. , Martin, Corby K. , Katzmarzyk, Peter T , Phelan, Suzanne , Redman, Leanne , Roe, Brian E , Stephens, Jacqueline M , Tate, Deborah F , Apovian, Caroline M , Martin, Corby K , Acosta, Andres , Gilbert, Jack A. , Laurienti, Paul J. , Lobstein, Tim , Ordovás, José María , Ryan, Donna H. , Tate, Deborah F.

Mayo Clinic

Obesity | September 18, 2025 | Volume: 33 | Issue: 11 | Pages: 2029-2045

10.1002/oby.70015 | PMID 40964812 Get It

ABSTRACT Precision medicine approaches have gained attention for their potential to more effectively manage obesity by tailoring diagnosis and treatment strategies to individual characteristics, including genetic background, phenotypes, metabolic profiles, and environmental exposures. The current review evaluates the evidence for precision medicine in weight management by summarizing the proceedings of a Pennington Biomedical Scientific Symposium titled “Precision Prevention, Diagnostics, and Treatment of Obesity: Pipedream or Reality?” This review discusses the extent to which we can classify and predict obesity risk based on individual‐level factors; whether we have the diagnostic capability to prospectively identify people who will benefit most from specific interventions; whether prospective trials demonstrate superior prevention and treatment of obesity when precision approaches are applied; and whether evidence is sufficient to guide policy decisions. Expert opinions were presented on the current evidence of precision medicine for obesity to collectively evaluate key barriers and opportunities for implementation of precision approaches in clinical and public health settings.
Cost‐Utility Analysis of a Group Mindfulness Program Compared to an Education Support Program for Breast Cancer Survivors With Cognitive Impairment: Evidence From a Randomized Controlled Trial
Tate, Rio , Park, Jong Y. , Hueluer, Gizem, Nguyen, Anh , Veal, Britney , Joshi, Anisha, Krothapalli, Mahathi, Nidamanur, Sreenidhi, Cox, Charles, Padgett, Lynne, Bornstein, Elizabeth, Lucas, Jean M., Fonseca, Tamela , Donovan, Kristine A. , Chamkeri, Ramya, Reich, Richard R. , Park, Jong Y , Veal, Britney , Fonseca, Tamela , Meng, Hongdao , Lengacher, Cecile A. , Rodriguez, Carmen S , Kip, Kevin E. , Morgan, Sandra P. , Tinsley, Sara , Cox, Charles E., Moscoso, Manolete S.

Mayo Clinic

Psycho-Oncology | July 23, 2025 | Volume: 34 | Issue: 7 | Pages: No page available

10.1002/pon.70220 | PMID 40696563 Get It

ABSTRACTObjectiveTo conduct an economic evaluation of a group mindfulness program compared to an education support program for breast cancer survivors (BCS).MethodsThe cost‐utility analysis (cost per quality‐adjusted life year [QALY]) was performed from a single‐center randomized controlled trial in the United States. Data from 181 BCS were included in the analysis (91 from the mindfulness‐based stress reduction for breast cancer, MBSR(BC) and 90 from the Breast Cancer Education Support, (BCES)). Analyses were conducted from two perspectives: societal and healthcare system. The EuroQol EQ‐5D‐5L was used to measure quality of life and the Client Service Receipt Inventory (CSRI) was used to measure health services utilization from baseline through 26 weeks. The impact of MBSR(BC) on health services utilization and costs was estimated with generalized linear models.ResultsIn the reference case analyses (societal perspective), the average total cost in the MBSR(BC) group was $5744 compared with $6140 in the BCES group. At the end of follow‐up, the MBSR(BC) group dominated BCES in terms of Incremental Cost Utility Ratio (ICUR), with MBSR(BC) providing an incremental cost of −$541 (95% CI: −$3400, $2318) and a 0.021 QALY (95% CI: −0.014, 0.055). Net monetary benefit (NMB) analysis showed that MBSR(BC) has a higher probability of achieving positive NMB across a range of possible societal willingness‐to‐pay for improving quality of life.ConclusionsOur findings suggest that MBSR(BC) is likely to be cost‐effective for breast cancer survivors over 6 months. Cost savings primarily resulted from reduced ER and hospital admissions and tests.
Executive Summary of a Focused Update to the Clinical Practice Guidelines for the Prevention and Management of Pain, Anxiety, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU
Lewis, Kimberley , Balas, Michele C. , Stollings, Joanna L. , McNett, Molly , Girard, Timothy D. , Chanques, Gérald , Weinhouse, Gerald L., Brummel, Nathan E., Duby, Jeremiah J. , Hall-Melnychuk, Erin L., Krupp, Anna , Louzon, Patricia , Tate, Judith A. , Young, Bethany , Jennings, Ron, Hines, Anitra, Ross, Chris, Carayannopoulos, Kallirroi Laiya , Aldrich, Janet , Girard, Timothy D , Kho, Michelle E. , Pandharipande, Pratik , Brummel, Nathan E. , Chlan, Linda L. , Cordoza, Makayla L. , Gélinas, Céline , Ross, Chris, Aldrich, J. Matthew

Mayo Clinic

Critical Care Medicine | February 21, 2025 | Volume: 53 | Issue: 3 | Pages: e701-e710

10.1097/ccm.0000000000006573 | PMID 39982138 Get It

A Focused Update to the Clinical Practice Guidelines for the Prevention and Management of Pain, Anxiety, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU
Lewis, Kimberley , Balas, Michele C. , Stollings, Joanna L. , McNett, Molly , Girard, Timothy D., Chanques, Gérald , Kho, Michelle E. , Weinhouse, Gerald L., Brummel, Nathan E., Duby, Jeremiah J. , Hall-Melnychuk, Erin L., Krupp, Anna , Louzon, Patricia , Tate, Judith A. , Young, Bethany , Jennings, Ron, Hines, Anitra, Ross, Chris, Carayannopoulos, Kallirroi Laiya , Aldrich, Janet , Girard, Timothy D. , Girard, Timothy D , Pandharipande, Pratik , Brummel, Nathan E. , Chlan, Linda L. , Cordoza, Makayla L. , Gélinas, Céline , Aldrich, J. Matthew

Mayo Clinic

Critical Care Medicine | February 21, 2025 | Volume: 53 | Issue: 3 | Pages: e711-e727

10.1097/ccm.0000000000006574 | PMID 39982143 Get It

RATIONALE: Critically ill adults are at risk for a variety of distressing and consequential symptoms both during and after an ICU stay. Management of these symptoms can directly influence outcomes. OBJECTIVES: The objective was to update and expand the Society of Critical Care Medicine’s 2018 Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. PANEL DESIGN: The interprofessional inclusive guidelines task force was composed of 24 individuals including nurses, physicians, pharmacists, physiotherapists, psychologists, and ICU survivors. The task force developed evidence-based recommendations using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. Conflict-of-interest policies were strictly followed in all phases of the guidelines, including task force selection and voting. METHODS: The task force focused on five main content areas as they pertain to adult ICU patients: anxiety (new topic), agitation/sedation, delirium, immobility, and sleep disruption. Using the GRADE approach, we conducted a rigorous systematic review for each population, intervention, control, and outcome question to identify the best available evidence, statistically summarized the evidence, assessed the quality of evidence, and then performed the evidence-to-decision framework to formulate recommendations. RESULTS: The task force issued five statements related to the management of anxiety, agitation/sedation, delirium, immobility, and sleep disruption in adults admitted to the ICU. In adult patients admitted to the ICU, the task force issued conditional recommendations to use dexmedetomidine over propofol for sedation, provide enhanced mobilization/rehabilitation over usual mobilization/rehabilitation, and administer melatonin. The task force was unable to issue recommendations on the administration of benzodiazepines to treat anxiety, and the use of antipsychotics to treat delirium. CONCLUSIONS: The guidelines task force provided recommendations for pharmacologic management of agitation/sedation and sleep, and nonpharmacologic management of immobility in critically ill adults. These recommendations are intended for consideration along with the patient’s clinical status.
Establishing Consensus for Mohs Micrographic Surgical Techniques in the Treatment of Melanoma in Situ for Future Clinical Trials: A Modified Delphi Study
Curtis, K., Fakult, Nathan J., Strunck, Jennifer L. , Aasi, Sumaira Z. , Ahn, Christine , Alam, Murad, Bar, Anna, Behshad, Ramona, Bichakjian, Christopher K. , Bolotin, Diana, Boone, Susan L., Brewer, Jerry D., Carr, David R. , Castillo, Jason R., Christensen, Sean R. , Clark, Melanie A., Collins, Lindsey K., Demer, Addison M. , Eisen, Daniel B. , Feng, Hao , Firoz, Bahar, Grekin, Roy C. , Hirshburg, Jason M., Holmes, Todd, Huang, Conway C. , Jennings, Thomas , Konda, Sailesh , Leitenberger, Justin J. , Lewin, Jesse M., Ng, Elise, Orengo, Ida, Samie, Faramarz H. , Saylor, Drew K. , Soleymani, Teo, Tate, Jesalyn A. , Vidal, Nahid Y. , Vij, Alok , Wysong, Ashley , Xu, Yaohui G. , Carroll, Bryan T. , Curtis, Kristen K., Bordeaux, Jeremy S. , Carr, David R., Carucci, John A. , Jiang, Shang I. Brian , Maher, Ian A. , Sharon, Victoria R. , Swetter, Susan M. , Beek, Marta J. Van , Yu, Wesley Y.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 30, 2024 | Volume: 22 | Issue: 8 | Pages: No page available

10.6004/jnccn.2024.7036 | PMID 39079545 Get It

Background: Mohs micrographic surgery (MMS) is a promising treatment modality for melanoma in situ (MIS). However, variations in surgical technique limit the generalizability of existing data and may impede future study of MMS in clinical trials. Methods: A modified Delphi method was selected to establish consensus on optimal MMS techniques for treating MIS in future clinical trials. The Delphi method was selected due to the limited current data, the wide range of techniques used in the field, and the intention to establish a standardized technique for future clinical trials. A literature review and interviews with experienced MMS surgeons were performed to identify dimensions of the MMS technique for MIS that (1) likely impacted costs or outcomes of the procedure, and (2) showed significant variability between surgeons. A total of 8 dimensions of technical variation were selected. The Delphi process consisted of 2 rounds of voting and commentary, during which 44 expert Mohs surgeons across the United States rated their agreement with specific recommendations using a Likert scale. Results: Five of eight recommendations achieved consensus in Round 1. All 3 of the remaining recommendations achieved consensus in Round 2. Techniques achieving consensus in Round 1 included the use of a starting peripheral margin of ≤5 mm, application of immunohistochemistry, frozen tissue processing, and resecting to the depth of subcutaneous fat. Consensus on the use of Wood’s lamp, dermatoscope, and negative tissue controls was established in Round 2. Conclusions: This study generated 8 consensus recommendations intended to offer guidance for Mohs surgeons treating MIS. The adoption of these recommendations will promote standardization to facilitate comparisons of aggregate data in multicenter clinical trials.